Your session is about to expire
← Back to Search
Genetic Testing Disclosure Timing for Age-Related Macular Degeneration (MAGENTA Trial)
Phase 2
Waitlist Available
Led By Paul Bernstein, MD, PhD
Research Sponsored by Paul S. Bernstein
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Participants must be between 18 and 64 years of age.
Participants must be between 18 and 64 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and month 12
Awards & highlights
MAGENTA Trial Summary
This trial will test whether or not receiving AMD genetic testing leads people to make healthier lifestyle choices as measured by their carotenoid status.
Who is the study for?
This study is for Caucasian individuals aged 18-64, with or without a family history of Age-related Macular Degeneration (AMD). It's not open to those who have AMD themselves, are non-Caucasian, work in eye care, had previous genetic testing for AMD risk, plan to have cataract surgery soon, or have major psychiatric disorders.Check my eligibility
What is being tested?
The trial is examining the effect of knowing one's genetic risk for AMD on lifestyle choices. Participants will receive their genetic test results either early or late in the study to see if and how this knowledge influences their behavior regarding eye health.See study design
What are the potential side effects?
Since this trial involves only the disclosure of genetic testing results rather than medication or procedures, there are no direct physical side effects. However, learning about personal genetic risks can sometimes cause anxiety or stress.
MAGENTA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 18 and 64 years old.
Select...
I am between 18 and 64 years old.
Select...
I am Caucasian, as required for the genetic test's accuracy.
MAGENTA Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline and month 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and month 12
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in skin carotenoid status in response to genetic risk disclosure as measured by Reflectance Spectroscopy
Change in skin carotenoid status in response to genetic risk disclosure as measured by Resonance Raman Spectroscopy
Secondary outcome measures
Chang in serum carotenoid status in response to genetic risk disclosure
Change in ocular carotenoid status in response to genetic risk disclosure as measured by Macular Pigment Optical Density
Change in ocular carotenoid status in response to genetic risk disclosure as measured by Macular Pigment Optical Volume
MAGENTA Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Early Genetic Results DisclosureExperimental Treatment1 Intervention
Early disclosure group receives results of genetic testing at Month 1
Group II: Late Genetic Results DisclosureActive Control1 Intervention
Late disclosure group receives results of genetic testing at Month 12
Find a Location
Who is running the clinical trial?
Paul S. BernsteinLead Sponsor
2 Previous Clinical Trials
55 Total Patients Enrolled
Paul Bernstein, MD, PhDPrincipal InvestigatorUniversity of Utah Moran Eye Center
2 Previous Clinical Trials
10,065 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My family has a history of age-related macular degeneration (AMD).I am between 18 and 64 years old.I am between 18 and 64 years old.I have been genetically tested for AMD risk before.I am expecting to have cataract surgery within the next year.I am Caucasian, as required for the genetic test's accuracy.I may or may not have a family history of AMD.I have a history of age-related macular degeneration (AMD).
Research Study Groups:
This trial has the following groups:- Group 1: Early Genetic Results Disclosure
- Group 2: Late Genetic Results Disclosure
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger